Eli Lilly-backed IpiNovyx Bio emerges with $10M for 2023 clinical entry

IpiNovyx Bio is launching with $10 million in seed funding from Eli Lilly, Viva Biotech's incubator and other venture capital firms, aiming to take its first candidate into the clinic in 2023. The company is going after inflammatory and autoimmune diseases.

Related Keywords

New York ,United States ,Cornell University ,Alexandria ,Al Iskandariyah ,Egypt ,Marc Appel ,Franck Barrat ,Carl Nathan ,Eli Lilly ,Ipinovyx Bio ,Hospital For Special Surgery Research Institute ,Weill Department ,Novartis ,New York City ,Orange Grove Bio ,Gang Lin ,Weill Cornell Medicine ,Special Surgery Research ,Anji Pharma ,Viva Biotech ,Haya Therapeutics ,Orange Grove ,Opaleye Management ,Alexandria Venture ,Venture Capital ,Weill Cornell Medical College ,Funding ,Small Molecules ,Autoimmune Disease ,Inflammatory Diseases ,Startups ,Immune System , ,